Genfit Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume378 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GNFTF News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Genfit logo

About Genfit

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Genfit (OTCMKTS:GNFTF) Frequently Asked Questions

What stocks does MarketBeat like better than Genfit?

Wall Street analysts have given Genfit a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genfit wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Genfit?

Genfit saw a increase in short interest in August. As of August 31st, there was short interest totaling 8,200 shares, an increase of 115.8% from the August 15th total of 3,800 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 82.0 days.
View Genfit's Short Interest

How has Genfit's stock price been impacted by Coronavirus?

Genfit's stock was trading at $14.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNFTF shares have decreased by 73.7% and is now trading at $3.71.
View which stocks have been most impacted by COVID-19

Who are Genfit's key executives?

Genfit's management team includes the following people:
  • Pascal Prigent, CEO & EVP-Marketing & Development
  • Dean W. Hum, Chief Operating Officer
  • Thomas Baetz, Chief Financial Officer
  • Carol L. Addy, Chief Medical Officer
  • Stefanie Magner, Chief Compliance Officer

Who are some of Genfit's key competitors?

What is Genfit's stock symbol?

Genfit trades on the OTCMKTS under the ticker symbol "GNFTF."

How do I buy shares of Genfit?

Shares of GNFTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genfit's stock price today?

One share of GNFTF stock can currently be purchased for approximately $3.71.

How many employees does Genfit have?

Genfit employs 130 workers across the globe.

What is Genfit's official website?

The official website for Genfit is www.genfit.com.

Where are Genfit's headquarters?

Genfit is headquartered at Parc Eurasante, Loos, Hauts-de-France 59120.

How can I contact Genfit?

Genfit's mailing address is Parc Eurasante, Loos, Hauts-de-France 59120. The company can be reached via phone at (332) 016-4000.

This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.